Your browser is no longer supported. Please, upgrade your browser.
SpringWorks Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.17 Insider Own3.10% Shs Outstand48.59M Perf Week-10.90%
Market Cap2.76B Forward P/E- EPS next Y-3.81 Insider Trans-41.10% Shs Float37.93M Perf Month-21.58%
Income-106.60M PEG- EPS next Q-0.88 Inst Own94.80% Short Float6.93% Perf Quarter-8.15%
Sales35.00M P/S78.88 EPS this Y10.50% Inst Trans0.41% Short Ratio6.84 Perf Half Y-34.28%
Book/sh9.60 P/B5.80 EPS next Y-15.10% ROA-19.90% Target Price116.00 Perf Year-33.69%
Cash/sh8.63 P/C6.45 EPS next 5Y- ROE-20.70% 52W Range51.72 - 96.48 Perf YTD-10.18%
Dividend- P/FCF- EPS past 5Y- ROI-8.30% 52W High-42.30% Beta-
Dividend %- Quick Ratio15.40 Sales past 5Y- Gross Margin- 52W Low7.64% ATR4.56
Employees142 Current Ratio15.40 Sales Q/Q- Oper. Margin- RSI (14)41.06 Volatility7.43% 7.83%
OptionableYes Debt/Eq0.00 EPS Q/Q-64.40% Profit Margin- Rel Volume1.39 Prev Close54.24
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume383.74K Price55.67
Recom2.00 SMA20-7.46% SMA50-15.49% SMA200-22.73% Volume531,561 Change2.64%
Jan-19-21Reiterated H.C. Wainwright Buy $87 → $101
Oct-29-20Reiterated H.C. Wainwright Buy $58 → $73
May-05-20Initiated Barclays Overweight $48
Mar-19-20Upgrade H.C. Wainwright Neutral → Buy $40 → $60
Mar-04-20Downgrade H.C. Wainwright Buy → Neutral $40
Jan-21-20Reiterated H.C. Wainwright Buy $34 → $40
Dec-04-19Initiated H.C. Wainwright Buy
Oct-08-19Initiated Wedbush Outperform $33
Oct-08-19Initiated JP Morgan Overweight $32
Oct-08-19Initiated Goldman Buy $37
Oct-08-19Initiated Cowen Outperform
Jan-12-22 01:21PM  
Jan-04-22 06:30AM  
Dec-27-21 09:38PM  
Dec-17-21 05:38PM  
Dec-15-21 08:53AM  
Dec-13-21 02:24PM  
Dec-10-21 09:24AM  
Dec-06-21 06:30AM  
Nov-29-21 06:30AM  
Nov-23-21 06:30AM  
Nov-10-21 09:35AM  
Nov-04-21 06:30AM  
Oct-27-21 06:30AM  
Oct-20-21 06:45AM  
Sep-29-21 08:47AM  
Sep-07-21 12:16PM  
Aug-30-21 06:30AM  
Aug-13-21 10:24AM  
Aug-04-21 06:30AM  
Aug-03-21 09:00AM  
Jul-27-21 08:00AM  
Jul-20-21 07:30AM  
Jul-19-21 12:08PM  
Jun-29-21 08:46AM  
Jun-28-21 07:00AM  
Jun-19-21 07:00AM  
Jun-16-21 06:40AM  
Jun-15-21 04:05PM  
Jun-10-21 09:04AM  
Jun-08-21 07:08AM  
Jun-07-21 06:30AM  
Jun-01-21 06:30AM  
May-14-21 06:30AM  
May-10-21 06:30AM  
May-06-21 06:30AM  
Apr-12-21 08:30AM  
Apr-05-21 08:18AM  
Apr-01-21 09:17AM  
Mar-28-21 12:44PM  
Mar-22-21 06:30AM  
Mar-12-21 06:07PM  
Mar-08-21 06:22AM  
Feb-25-21 08:16AM  
Feb-22-21 06:30AM  
Feb-04-21 06:30AM  
Jan-05-21 06:30AM  
Dec-19-20 02:44PM  
Dec-17-20 01:43PM  
Dec-15-20 09:00AM  
Dec-07-20 07:07AM  
Nov-24-20 06:30AM  
Nov-12-20 07:04AM  
Oct-26-20 07:30AM  
Oct-16-20 03:15PM  
Oct-13-20 04:05PM  
Oct-12-20 08:50AM  
Oct-07-20 08:25PM  
Oct-06-20 04:22PM  
Oct-05-20 06:30AM  
Sep-22-20 04:05PM  
Sep-21-20 07:00AM  
Sep-18-20 06:30AM  
Sep-16-20 06:30AM  
Sep-14-20 06:30AM  
Aug-12-20 04:45PM  
Aug-04-20 06:30AM  
Jul-22-20 06:30AM  
Jun-28-20 04:53PM  
Jun-22-20 09:00AM  
Jun-17-20 08:30AM  
Jun-10-20 06:14AM  
Jun-02-20 06:30AM  
May-26-20 06:30AM  
May-12-20 07:30AM  
Apr-15-20 02:49PM  
Mar-18-20 06:30AM  
Mar-12-20 04:30PM  
Feb-27-20 07:14AM  
Feb-18-20 06:30AM  
Jan-13-20 06:00AM  
Jan-06-20 06:30AM  
Dec-16-19 04:38PM  
Dec-13-19 10:07AM  
Dec-09-19 10:00AM  
Nov-12-19 08:00AM  
Oct-24-19 06:30AM  
Sep-27-19 08:00PM  
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; collaboration agreement with Ab Magnitude Ventures Group, LLC and Ab Magnitude Fund, LP; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology; and clinical trial collaboration agreement with Seagen Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Islam SaqibChief Executive OfficerOct 20Sale58.6710,083591,527779,218Oct 20 07:14 PM
Islam SaqibChief Executive OfficerOct 19Sale58.8114,077827,873769,135Oct 19 07:27 PM
Islam SaqibChief Executive OfficerOct 18Sale58.5938,3402,246,505783,212Oct 19 07:27 PM
Smith L. MaryChief Development OfficerOct 13Option Exercise2.3010,00023,000177,511Oct 13 08:24 PM
Smith L. MaryChief Development OfficerOct 13Sale55.9710,000559,675167,511Oct 13 08:24 PM
Pichl DanielChief People OfficerSep 08Option Exercise43.102,32099,9929,236Sep 09 05:15 PM
Bain Capital Life Sciences Inv10% OwnerAug 10Sale70.251,000,00070,250,0004,831,307Aug 12 08:38 PM
Islam SaqibChief Executive OfficerJul 20Sale77.6818,5721,442,751821,552Jul 20 07:34 PM
Islam SaqibChief Executive OfficerJul 19Sale76.0943,9283,342,438840,124Jul 20 07:34 PM
Smith L. MaryChief Development OfficerJul 13Option Exercise2.3010,00023,000177,511Jul 14 04:28 PM
Smith L. MaryChief Development OfficerJul 13Sale80.8810,000808,777167,511Jul 14 04:28 PM
Edris BadreddinChief Operating OfficerJul 01Sale85.3532,0002,731,088301,541Jul 01 06:30 PM
ORBIMED ADVISORS LLC10% OwnerJul 01Sale85.0115,9591,356,6756,028,307Jul 06 04:42 PM
ORBIMED ADVISORS LLC10% OwnerJun 28Sale85.176,502553,7756,044,266Jun 30 09:01 PM
ORBIMED ADVISORS LLC10% OwnerJun 25Sale85.1422,3341,901,5176,050,768Jun 25 07:11 PM
ORBIMED ADVISORS LLC10% OwnerJun 24Sale85.2234,2002,914,5246,073,102Jun 25 07:11 PM
ORBIMED ADVISORS LLC10% OwnerJun 23Sale85.001008,5006,107,302Jun 25 07:11 PM
ORBIMED ADVISORS LLC10% OwnerJun 10Sale85.0930,8522,625,1976,107,402Jun 14 05:58 PM
ORBIMED ADVISORS LLC10% OwnerJun 09Sale85.335,049430,8316,138,254Jun 09 06:26 PM
ORBIMED ADVISORS LLC10% OwnerJun 08Sale85.3742,6333,639,5796,143,303Jun 09 06:26 PM
ORBIMED ADVISORS LLC10% OwnerJun 07Sale84.9037131,4986,185,936Jun 09 06:26 PM
SQUINTO STEPHEN PDirectorApr 28Sale76.2019,2311,465,437125,728Apr 28 08:18 PM
SQUINTO STEPHEN PDirectorApr 27Sale75.0520115,085144,959Apr 28 08:18 PM
Islam SaqibChief Executive OfficerApr 20Sale66.3924,0751,598,279884,052Apr 20 06:51 PM
Islam SaqibChief Executive OfficerApr 19Sale69.0438,4252,652,827908,127Apr 20 06:51 PM
SQUINTO STEPHEN PDirectorApr 15Sale75.011,05779,291145,160Apr 19 06:07 AM
SQUINTO STEPHEN PDirectorApr 14Sale75.0851138,365146,217Apr 19 06:07 AM
Smith L. MaryChief Development OfficerApr 13Option Exercise2.3010,00023,000177,511Apr 13 08:21 PM
Smith L. MaryChief Development OfficerApr 13Sale68.0710,000680,723167,511Apr 13 08:21 PM
Bain Capital Life Sciences Inv10% OwnerMar 09Sale71.501,450,000103,675,0005,831,307Mar 11 04:30 PM
ORBIMED ADVISORS LLC10% OwnerMar 01Sale83.191,220,000101,491,8006,186,307Mar 03 06:55 PM